Michael A. Morse

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.8K citations · Full text

Medicine, Genetics, Oncology +14

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Christine H. Chung, Beloo Mirakhur, Emily Chan et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text

Life Sciences, Immunology, Oncology +15

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

Michael A. Morse, Jennifer Garst, Takuya Osada et al. · Journal of Translational Medicine · 2005 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +15

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono et al. · The Lancet Oncology · 2016 · 685 citations · Full text

Medicine, Oncology, Pharmacotherapy +12